Jazz Pharmaceuticals PLC
JAZZ166.990USD
+0.990+0.60%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.14BMarket Cap
LossP/E TTM
More Details of Jazz Pharmaceuticals PLC Company
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC Info
Ticker SymbolJAZZ
Company nameJazz Pharmaceuticals PLC
IPO dateJan 18, 2012
CEOGala (Renee D)
Number of employees2800
Security typeOrdinary Share
Fiscal year-endJan 18
AddressFifth Floor, Waterloo Exchange
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code- -
Phone35316347800
Websitehttps://www.jazzpharma.com/
Ticker SymbolJAZZ
IPO dateJan 18, 2012
CEOGala (Renee D)
Company Executives of Jazz Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.28%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
292.32K
-5.03%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.12K
-0.17%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
24.12K
-22.89%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
13.92K
+13.93%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
12.77K
+15.38%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.24K
-5.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
7.11K
+31.50%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.28%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
292.32K
-5.03%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.12K
-0.17%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
24.12K
-22.89%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Xywav
415.32M
39.72%
Epidiolex/epidyolex
251.73M
24.07%
Rylaze
100.66M
9.63%
Zepzelca
74.54M
7.13%
High-sodium oxybate AG royalty revenue
54.14M
5.18%
Other
149.32M
14.28%
By RegionUSD
Name
Revenue
Proportion
United States
936.28M
89.54%
Europe
82.76M
7.91%
All Others
26.67M
2.55%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Xywav
415.32M
39.72%
Epidiolex/epidyolex
251.73M
24.07%
Rylaze
100.66M
9.63%
Zepzelca
74.54M
7.13%
High-sodium oxybate AG royalty revenue
54.14M
5.18%
Other
149.32M
14.28%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.13%
Other
69.06%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.13%
Other
69.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.91%
Investment Advisor/Hedge Fund
34.93%
Hedge Fund
10.56%
Research Firm
3.49%
Individual Investor
3.02%
Pension Fund
1.77%
Venture Capital
1.30%
Bank and Trust
0.85%
Sovereign Wealth Fund
0.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1197
64.03M
105.38%
-5.21M
2025Q2
1199
63.76M
105.11%
-6.47M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
2023Q3
1158
61.08M
96.76%
-4.05M
2023Q2
1197
61.00M
95.34%
-4.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
6.07M
10%
+73.43K
+1.22%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.22M
8.61%
+11.23K
+0.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.54M
4.18%
+209.41K
+8.99%
Jun 30, 2025
Capital World Investors
2.54M
4.19%
+616.73K
+31.99%
Jun 30, 2025
LSV Asset Management
2.55M
4.21%
+87.58K
+3.55%
Jun 30, 2025
State Street Investment Management (US)
1.94M
3.19%
-31.20K
-1.59%
Jun 30, 2025
EcoR1 Capital, LLC
1.71M
2.81%
--
--
Jun 30, 2025
JP Morgan Asset Management
1.55M
2.55%
+46.92K
+3.12%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.63M
2.69%
+297.95K
+22.39%
Jun 30, 2025
Columbia Threadneedle Investments (US)
1.54M
2.54%
+186.67K
+13.80%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Cambria Cannabis ETF
4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.11%
iShares U.S. Pharmaceuticals ETF
3.08%
Invesco Pharmaceuticals ETF
2.94%
State Street SPDR S&P Pharmaceuticals ETF
2.83%
Abacus FCF International Leaders ETF
2.69%
First Trust NASDAQ Pharmaceuticals ETF
2.51%
Clough Hedged Equity ETF
2.4%
Alger Russell Innovation ETF
2.12%
VictoryShares Small Cap Free Cash Flow ETF
1.77%
View more
Cambria Cannabis ETF
Proportion4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion3.11%
iShares U.S. Pharmaceuticals ETF
Proportion3.08%
Invesco Pharmaceuticals ETF
Proportion2.94%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.83%
Abacus FCF International Leaders ETF
Proportion2.69%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.51%
Clough Hedged Equity ETF
Proportion2.4%
Alger Russell Innovation ETF
Proportion2.12%
VictoryShares Small Cap Free Cash Flow ETF
Proportion1.77%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Jazz Pharmaceuticals PLC?
The top five shareholders of Jazz Pharmaceuticals PLC are:
The Vanguard Group, Inc. holds 6.07M shares, accounting for 10.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.22M shares, accounting for 8.61% of the total shares.
Dimensional Fund Advisors, L.P. holds 2.54M shares, accounting for 4.18% of the total shares.
Capital World Investors holds 2.54M shares, accounting for 4.19% of the total shares.
LSV Asset Management holds 2.55M shares, accounting for 4.21% of the total shares.
The Vanguard Group, Inc. holds 6.07M shares, accounting for 10.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.22M shares, accounting for 8.61% of the total shares.
Dimensional Fund Advisors, L.P. holds 2.54M shares, accounting for 4.18% of the total shares.
Capital World Investors holds 2.54M shares, accounting for 4.19% of the total shares.
LSV Asset Management holds 2.55M shares, accounting for 4.21% of the total shares.
What are the top three shareholder types of Jazz Pharmaceuticals PLC?
The top three shareholder types of Jazz Pharmaceuticals PLC are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
How many institutions hold shares of Jazz Pharmaceuticals PLC (JAZZ)?
As of 2025Q3, 1197 institutions hold shares of Jazz Pharmaceuticals PLC, with a combined market value of approximately 64.03M, accounting for 105.38% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.27%.
What is the biggest source of revenue for Jazz Pharmaceuticals PLC?
In FY2025Q2, the Xywav business generated the highest revenue for Jazz Pharmaceuticals PLC, amounting to 415.32M and accounting for 39.72% of total revenue.
